Menu Close

News

NeuroCycle Therapeutics Awarded NIH HEAL Initiative Grant to Research a Novel Non-Addictive, Non-Opioid Treatment of Chronic Pain

Press Release

October 1, 2019

""NeuroCycle Therapeutics, Inc. (NCT) announced today that it has been awarded a grant from the Helping to End Addiction Long-termsm Initiative, or the NIH HEAL Initiativesm, to advance development of its novel non-addictive treatment of chronic musculoskeletal pain, which includes pain caused by osteo- and rheumatic arthritis, is one of the most common forms of chronic pain. Current therapies often provide insufficient pain relief, and many have adverse side effects. Furthermore, many patients use opioids as part of their pain control regimen and are at risk of developing Opioid Use Disorder, significantly contributing to the national opioid public health crisis. Effective treatments of chronic musculoskeletal pain that have no risk of misuse are urgently needed.

Learn more about the NIH HEAL Initiative grant »

NeuroCycle Therapeutics Awarded NIH SBIR Grant to Study Next-Generation Treatment of Dravet Syndrome

Press Release

February 13, 2019

synapse
Credit: Eraxion / iStock

NeuroCycle Therapeutics, Inc. (NCT) announced today that is has been awarded a $0.5M Small Business Innovation Research grant from the National institute of Neurological Disorders and Stroke (NINDS) to evaluate its advanced subtype-selective GABAA receptor modulators, NCT10004 and NCT10015, in models of Dravet Syndrome (Award Number R43NS107051). This grant builds upon the company’s strategy to develop a portfolio of small molecule drug candidates that maximize efficacy and minimize side effects through selective targeting of the central nervous system.

Learn more about the NIH SBIR grant »

Bayer Animal Health and NeuroCycle Therapeutics sign global license agreement

Press Release

September 12, 2018

Four people holding an emblem of a license agreement

Bayer Animal Health GmbH and NeuroCycle Therapeutics, Inc. (NCT) have signed a global license agreement to advance innovative allergy treatment options for companion animals. As part of the license agreement, Bayer will develop and commercialize novel compounds based on knowledge and intellectual property licensed and controlled by NCT.

View the full press release »

Massachusetts Life Sciences Innovation Day

Poster Presentation, Boston, MA

May 31, 2018

NeuroCycle Therapeutics, Inc. was selected to exhibit a poster at the Massachusetts Life Sciences Innovation (MALSI) Day on May 31, 2018. The event was billed as "the flagship event of life sciences in Massachusetts, jointly and actively put together by all the major organizations that are involved in starting and supporting the life sciences start-up ecosystem in the Commonwealth," we appreciated the opportunity to meet the people who make the Life Sciences such an exciting field.

Life Sciences Global Pitch Fest!

Pitch Presentation, Cambridge, MA

May 31, 2018

Jed Hubbs, Ph.D. and CEO of NeuroCycle Therapeutics participated in the Life Sciences Global Pitch Fest at the Novartis Institutes for BioMedical Research (NIBR) in Kendall on May 31, 2018. Every entrepreneur had 1 minute and 1 slide to present.

1st European Biotech Day with LabCentral

Presentation, Cambridge, MA

June 4, 2018

Jed Hubbs, Ph.D. and CEO of NeuroCycle Therapeutics gave a short presentation at the 1st European Biotech Day at LabCentral in Cambridge, MA. Hosted by the German Accelerator Life Sciences and LabCentral, the event featured panel discussions and a pitch competition from U.S. and European startups.